Clinical thiazolidinediones as PPARγ ligands with the potential for the prevention of cardiovascular disease in diabetes

Current Diabetes Reviews

Volumn 2, Issue 2, 2006, Pages 227-239

  de Dios, Stephanie T ^a   O'Brien, Richard C ^b   Little, Peter J ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Atherosclerosis; Cardiovascular disease; Glucose; PPAR ; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER A1; ACETYLSALICYLIC ACID; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CD36 ANTIGEN; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; GLICLAZIDE; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 6; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEOGLYCAN; REPAGLINIDE; RESISTIN; RETINOID X RECEPTOR; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; ANTIDIABETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROTIC PLAQUE; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HEART INFARCTION; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IN-STENT RESTENOSIS; LIPID STORAGE; LIVER TOXICITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; STRUCTURE ACTIVITY RELATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE; WEIGHT GAIN; ANIMAL; ANIMAL MODEL; DIABETIC ANGIOPATHY; INFLAMMATION; PHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION; MODELS, ANIMAL; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 33746130389     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339906776818622     Document Type: Review

References (172)

1. Furth AJ. Glycated proteins in diabetes. Br J Biomed Sci 1997; 54: 192-200.
2. Singh R, Barden A, Mori T, Beilin L. Advanced glycation endproducts: A review. Diabetologia 2001; 44: 129-46.
3. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
4. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002; 251: 87-101.
5. Schmidt AM, Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000; 2: 430-6.
6. Tomkin GH, Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis. Diabetes Metab Res Rev 2001; 17: 27-43.
7. Jagla A, Schrezenmeir J. Postprandial triglycerides and endothelial function. Exp Clin Endocrinol Diabetes 2001; 109: S533-47.
8. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-81.
9. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 2002; 90: 27G-33G.
10. Ceriello A, dello Russo P, Amstad P, Cerutti P. High Glucose Induces Antioxidant Enzymes in Human Endothelial Cells in Culture - Evidence Linking Hyperglycemia and Oxidative Stress. Diabetes 1996; 45: 471-7.
11. Ceriello A, Falleti E, Motz E, et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: The possible role of oxidative stress. Hormone Metabolism Research 1998; 30: 146-9.
12. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-5.
13. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
14. Jialal I, Devaraj S. Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Clin Chem 1996; 42: 498-506.
15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Bri Med J 1998; 317: 703-13.
16. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bri Med J 2000; 321: 405-12.
17. Cohen JD, Drury JH, Ostdiek J, et al. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? Am Heart J 2000; 139: 734-8.
18. Goguen JM, Leiter LA. Lipids and diabetes mellitus: a review of therapeutic options. Curr Med Res Opin 2002; 18 (Suppl) 1: s58-74.
19. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin 2004; 20: 1559-69.
20. Deferrari G, Ravera M, Berruti V, Leoncini G, Deferrari L. Optimizing therapy in the diabetic patient with renal disease: antihypertensive treatment. J Am Soc Nephrol 2004; 15 (Suppl) 1: S6-S11.
21. Camejo G, Olsson U, Hurt-Camejo E, Baharamian N, Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atheroscler Suppl 2002; 3: 3-9.
22. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809-17.
23. Hu D, Jablonski KA, Sparling YH, et al. Accuracy of lipoprotein lipids and apoproteins in predicting coronary heart disease in diabetic American Indians. The Strong Heart Study. Am Epidemiol 2002; 12: 79-85.
24. Haffner SM, Agostino RD Jr, Saad MF, et al. Carotid artery atherosclerosis in type-2 diabetic and non-diabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000; 85: 1395-400.
25. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med 1976; 295: 369-77.
26. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med 1976; 295: 420-5.
27. Ross R, Atherosclerosis - An inflammatory disease. N Engl J Med 1999; 340: 115-26.
28. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-4.
29. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15: 551-61.
30. Srinivasan SR, Vijayagopal P, Dalferes ER Jr, Abbate B, Radhakrishnamurthy B, Berenson GS. Dynamics of lipoprotein-glycosaminoglycan interactions in the atherosclerotic rabbit aorta in vivo. Biochim Biophys Acta 1984; 793: 157-68.
31. Vijayagopal P, Radhakrishnamurthy B, Srinivasan SR, McMurtrey J, Berenson GS. Proteoglycan synthesis and secretion by bovine aortic tissue in organ culture. Artery 1980; 6: 458-70.
32. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56: 265-94.
33. Duval C, Chinetti G, Trottein F, Fruchart J, Staels B. The role of PPARs in atherosclerosis. Trends Mol Med 2002; 8: 422.
34. Komers R, Vrana A. Thiazolidinediones- Tools for the research of metabolic syndrome X. Physiological reviews 1998; 47: 215-25.
35. Jha RJ. Thiazolidinediones - The new insulin enhancers. Clin Exp Hypertens 1999; 21: 157-66.
36. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997; 26: 553-73.
37. Kelly DP. The pleiotropic nature of the vascular PPAR gene regulatory pathway. Circ Res 2001; 89: 935-7.
38. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and non-diabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 365-71.
39. Chang MY, Potter-Perigo S, Tsoi C, Chait A, Wight TN. Oxidized low density lipoproteins regulate synthesis of monkey aortic smooth muscle cell proteoglycans that have enhanced native low density lipoprotein binding properties. J Biol Chem 2000; 275: 4766-73.
40. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26: 511-22.
41. Lebovitz HE. alpha-Glucosidase inhibitors. Endocrinol Metab Clin North Am 1997; 26: 539-51.
42. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-9.
43. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9.
44. Stumvoll M, Haring HU. Glitazones: clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-24.
45. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001; 52: 239-57.
46. Gale EA. Lessons from the glitazones: a story of drug development. Lancet 2001; 357: 1870-5.
47. Lebovitz HE. Differentiating members of the thiazolidinedione class: A focus on safety. Diabetes Metab Res Rev 2002; 18 Suppl 2: S23-9.
48. Parker JC. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. Adv Drug Deli Rev 2002; 54: 1173-97.
49. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994; 43: 1203-10.
50. Connor SC, Hughes MG, Moore G, Lister CA, Smith SA. Antidiabetic efficacy of BRL 49653, a potent orally active insulin sensitizing agent, assessed in the C57BL/KsJ db/db diabetic mouse by non-invasive 1H NMR studies of urine. J Pharm Pharmacol 1997; 49: 336-44.
51. Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998; 284: 751-9.
52. Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K. Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia. Circulation 2001; 104: 455-60.
53. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
54. Reasner CA. Where thiazolidinediones will fit. Diabetes Metab Res Rev 2002; 18 (Suppl) 2: S30-5.
55. Johnson MD, Campbell LK, Campbell RK. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother 1998; 32: 337-48.
56. Lohray BB, Bhushan V, Rao BP, et al. Novel euglycemic and hypolipidemic agents. 1. J Med Chem 1998; 41: 1619-30.
57. Uwaifo GI, Ratner RE. The roles of insulin resistance, hyperinsulinemia, and thiazolidinediones in cardiovascular disease. Am J Med 2003; 115 (Suppl) 8A: 12S-9S.
58. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18 (Suppl) 2: S10-5.
59. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
60. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.
61. Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001; 24: 392-7.
62. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879-87.
63. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-9.
64. Clarke SD, Thuillier P, Baillie RA, Sha X. Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors. Am J Clin Nutr 1999; 70: 566-71.
65. Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 2003; 42: 664-8.
66. Nolte RT, Wisely GB, Westin S, et al. Ligand Binding and co-activator assembly of the Peroxisome Proliferator-activated Receptor-γ. Nature 1998; 395: 137-43.
67. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem 1998; 273: 31108-12.
68. Collingwood TN, Urnov FD, Wolffe AP. Nuclear receptors: co-activators, co-repressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 1999; 23: 255-75.
69. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129: 823-34.
70. Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome profiferators. Annu Rev Pharmacol Toxicol 2000; 40: 491-518.
71. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature 2000; 405: 421-4.
72. Chawla A, Lee CH, Barak Y, et al. PPARdelta is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 2003; 100: 1268-73.
73. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-40.
74. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998; 95: 7614-9.
75. Moore KJ, Rosen ED, Fitzgerald ML, et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 2001; 7: 41-7.
76. Law RE, Goetze S, Xi XP, et al. Expression and Function of PPARgamma in Rat and Human Vascular Smooth Muscle Cells. Circulation 2000; 101: 1311-8.
77. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354-66.
78. Singh Ahuja H, Liu S, Crombie DL, et al. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 2001; 59: 765-73.
79. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-51.
80. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
81. Glass CK, Witztum JL. Atherosclerosis: The road ahead. Cell 2001; 104: 503-16.
82. Jiang C, Ting A, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
83. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 546-51.
84. Jackson SM, Parhami F, Xi XP, et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 1999; 19: 2094-104.
85. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-8.
86. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52.
87. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
88. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48-52.
89. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001; 12: 511-8.
90. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circulation Research 1998; 83: 1097-103.
91. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, Little PJ. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003; 107: 2548-50.
92. Peuler JD, Phare SM, Iannucci AR, Hadorek MJ. Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation. Am J Hypertens 1996; 9: 188-92.
93. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1->S transition in vascular smooth muscle cells. J Biol Chem 2000; 275: 22435-41.
94. Bruemmer D, Yin F, Liu J, Berger JP, et al. Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. Mol Endocrinol 2003; 17: 1005-18.
95. Palakurthi SS, Aktas H, Grabissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001; 61: 6213-8.
96. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPAR-gamma modulators (SPARMs). Trends Mol Med 2001; 7: 395-400.
97. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-4.
98. O'Brien KD, Olin KL, Alpers CE, et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: Co-localization of biglycan with apolipoproteins. Circulation 1998; 98: 519-27.
99. Williams KJ, Tabas I. Atherosclerosis and inflammation. Science 2002; 297: 521-2.
100. Camejo G, Fager G. Rosengren B, Hurt-Camejo E, Bondjers G. Binding of low density lipoproteins by proteoglycans synthesized by proliferating and quiescent human arterial smooth muscle cells. J Biol Chem 1993; 268: 14131-7.
101. Wight TN. Cell biology of arterial proteoglycans. Arteriosclerosis 1989; 9: 1-20.
102. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998; 139: 205-22.
103. Little PJ, Tannock L, Olin KL, Chait A, Wight TN. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol 2002; 22: 55-60.
104. Tannock L, Little PJ, Wight TN, Chait A. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res 2002; 43: 149-57.
105. Rosen ED, Spiegelman BM. PPAR-gamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4.
106. Marx N, Froehlich J, Siam L. et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-8.
107. Plutzky J. Atherosclerotic plaque rupture: emerging insights and opportunities. Am J Cardiol 1999; 84: 15J-20J.
108. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
109. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001; 21: 1891-5.
110. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk 2001; 8: 203-10.
111. Beckman J, Raji A, Plutzky J. Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities. Curr Opin Cardiol 2003; 18: 479-85.
112. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996; 98: 1897-905.
113. Igarashi M, Takeda Y, Ishibashi N, Mori S, Tominaga M, Saito Y. Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Hormone Metabolism Research 1997; 29: 444-9.
114. Shinohara E, Kihara S, Ouchi N, Funahashi T, Nakamura T. Troglitazone suppresses intimal formation following balloon injury in insulin-resistant Zucker fatty rats. Atherosclerosis 1998; 136: 275-9.
115. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001; 21: 372-7.
116. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106: 523-31.
117. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 2004; 43: 297-305.
118. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717-26.
119. Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 1996; 45: 1168-73.
120. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51: 1507-14.
121. Tao L, Liu HR, Gao E, et al. Anti-oxidative, anti-nitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 2003; 108: 2805-11.
122. Liu HR, Tao L, Gao E, et al. Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion. Cardiovasc Res 2004; 62: 135-44.
123. Yue Tl TL, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-94.
124. Ito H, Nakano A, Kinoshita M, Matsumori A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest 2003; 83: 1715-21.
125. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000; 101: 1165-71.
126. Thiemermann C, Wayman NS. Menarini Academy Cardiovascular Research Awards in Basic Science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size. Med Sci Monit 2001; 7: 787-9.
127. Wayman NS, Hattori Y, McDonald MC, et al. Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002; 16: 1027-40.
128. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988; 11: 821-7.
129. Aroda VR, Henry RR. Thiazolidinediones: Potential link between insulin resistance and cardiovascular disease. Diabetes Spectrum 2003; 16: 120-5.
130. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect. J Clin Invest 1995; 96: 354-60.
131. Tack CJJ, Ong MKE, Lutterman JA, Smits P. Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: Effects of troglitazone. Diabetologia 1998; 41: 569-76.
132. Shaffer S, Rubin CJ, Zhu E. Study Group-Pioglitazone 001: The effects of pioglitazone on the lipid profile in patients with type 2 diabetes. Diabetes 2000; 48 (Suppl. 1): 508P.
133. Saleh YM, Mudaliar SR, Henry RR. Metabolic and vascular effects of the thiazolidinedione troglitazone. Diabetes Reviews 1999; 7: 55-76.
134. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708-11.
135. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-603.
136. Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev 2005; 6: 13-21.
137. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001; 108: 1875-81.
138. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-703.
139. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
140. Cnop M, Havel PJ, Utzschneider KM, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003; 46: 459-69.
141. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 279: 12152-62.
142. Milan G, Granzotto M, Scarda A, et al. Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 2002; 10: 1095-103.
143. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
144. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002; 51: 2968-74.
145. Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-9.
146. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 2002; 87: 5662-7.
147. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
148. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
149. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
150. Nigro J, Ballinger M, Osman N, Dart A, Little PJ. Anti-atherogenic role of peroxisome proliferator activated receptor ligands. Current Cardiology Reviews (In Press) 2005.
151. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-35.
152. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-63.
153. McVeigh GE, Brennan GM, Johnson GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-6.
154. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
155. Espeland MA, O'Leary D H, Terry JG, Morgan T, Evans G, Mudra H. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005; 6: 3.
156. Uchiyama-Tanaka Y, Mori Y, Kishimoto N, et al. Comparison of the effects of quinapril and losartan on carotid artery intima-media thickness in patients with mild-to-moderate arterial hypertension. Kidney Blood Press Res 2005; 28: 111-6.
157. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-20.
158. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-6.
159. Schofer J, Schluter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol 2000; 35: 1554-9.
160. Moses JW, Moussa I, Leon MB, et al. Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial). Am J Cardiol 2002; 90: 243-7.
161. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654-60.
162. Nakamura T, Matsuda T, Kawagoe Y, et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382-6.
163. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525-31.
164. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 2003; 76: 891-9.
165. Srikanthan P, Hsueh WA, Kobashigawa JA. Impact of rosiglitazone on vascular events, atherosclerosis and allograft rejection in cardiac transplant patients with diabetes. Diabetes 2004; 53 (Suppl 2): A146.
166. Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005; 103: 1-9.
167. Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-43.
168. Halimi S, Charpentier G, Grimaldi A, et al. Effect on compliance, acceptability of blood glucose self-monitoring and HbA(1c) of a self-monitoring system developed according to patients wishes. The ACCORD study. Diabetes Metab 2001; 27: 681-7.
169. Home P, Gibb J, Committee for the RECORD study Steering Committee. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD): A long-term cardiovascular outcome study. Diabetes 2002; 50: A487.
170. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 2003; 107: 636-42.
171. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72.
172. Tannock LR, Little PJ, Tsoi C, Barrett PHR, Wight TN, Chait A. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia 2004; 47: 837-43.